RESUMO
The cancer-testis antigen NY-ESO-1 is a potential target antigen for immune therapy expressed in a subset of patients with multiple myeloma. We generated chimeric antigen receptors (CARs) recognizing the immunodominant NY-ESO-1 peptide 157-165 in the context of HLA-A*02:01 to re-direct autologous CD8(+) T cells towards NY-ESO-1(+) myeloma cells. These re-directed T cells specifically lysed NY-ESO-1(157-165)/HLA-A*02:01-positive cells and secreted IFNγ. A total of 40% of CCR7(-) re-directed T cells had an effector memory phenotype and 5% a central memory phenotype. Based on CCR7 cell sorting, effector and memory CAR-positive T cells were separated and CCR7(+) memory cells demonstrated after antigen-specific re-stimulation downregulation of CCR7 as sign of differentiation towards effector cells accompanied by an increased secretion of memory signature cytokines such as IL-2. To evaluate NY-ESO-1 as potential target antigen, we screened 78 bone marrow biopsies of multiple myeloma patients where NY-ESO-1 protein was found to be expressed by immunohistochemistry in 9.7% of samples. Adoptively transferred NY-ESO-1-specific re-directed T cells protected mice against challenge with endogenously NY-ESO-1-positive myeloma cells in a xenograft model. In conclusion, re-directed effector- and central memory T cells specifically recognized NY-ESO-1(157-165)/ HLA-A*02:01-positive cells resulting in antigen-specific functionality in vitro and in vivo.
Assuntos
Antígenos de Neoplasias/imunologia , Linfócitos T CD8-Positivos/imunologia , Imunoterapia , Mieloma Múltiplo/terapia , Proteínas de Neoplasias/imunologia , Fragmentos de Peptídeos/imunologia , Receptores de Antígenos de Linfócitos T/imunologia , Animais , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/metabolismo , Linfócitos T CD8-Positivos/metabolismo , Linfócitos T CD8-Positivos/transplante , Linhagem Celular Tumoral , Terapia Genética , Humanos , Memória Imunológica , Interferon gama/genética , Interferon gama/metabolismo , Interleucina-2/genética , Interleucina-2/metabolismo , Camundongos , Mieloma Múltiplo/imunologia , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Fragmentos de Peptídeos/genética , Fragmentos de Peptídeos/metabolismo , Receptores de Antígenos de Linfócitos T/genética , Receptores CCR7/genética , Receptores CCR7/metabolismo , Transdução GenéticaRESUMO
BACKGROUND: Aggressive mature B-cell non-Hodgkin's lymphomas (BCL) sharing features of Burkitt's lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) (intermediate BL/DLBCL) but deviating with respect to one or more characteristics are increasingly recognized. The limited knowledge about these biologically heterogeneous lymphomas hampers their assignment to a known entity, raising incertitude about optimal treatment approaches. We therefore searched for discriminative, prognostic, and predictive factors for their better characterization. PATIENTS AND METHODS: We analyzed 242 cytogenetically defined aggressive mature BCL for differential protein expression. Marker selection was based on recent gene-expression profile studies. Predictive models for diagnosis were established and validated by a different set of lymphomas. RESULTS: CSE1L- and inhibitor of DNA binding-3 (ID3)-overexpression was associated with the diagnosis of BL and signal transduction and transcription-3 (STAT3) with DLBCL (P<0.001 for all markers). All three markers were associated with patient outcome in DLBCL. A new algorithm discriminating BL from DLBCL emerged, including the expression of CSE1L, STAT3, and MYC translocation. This 'new classifier' enabled the identification of patients with intermediate BL/DLBCL who benefited from intensive chemotherapy regimens. CONCLUSION: The proposed algorithm, which is based on markers with reliable staining properties for routine diagnostics, represents a novel valid tool in separating BL from DLBCL. Most interestingly, it allows segregating intermediate BL/DLBCL into groups with different treatment requirements.
Assuntos
Algoritmos , Biomarcadores Tumorais/genética , Linfoma de Burkitt/diagnóstico , Proteína de Suscetibilidade a Apoptose Celular/genética , Genes myc , Linfoma Difuso de Grandes Células B/diagnóstico , Fator de Transcrição STAT3/genética , Western Blotting , Linfoma de Burkitt/genética , Feminino , Humanos , Imuno-Histoquímica , Hibridização in Situ Fluorescente , Linfoma Difuso de Grandes Células B/genética , Masculino , Pessoa de Meia-Idade , PrognósticoRESUMO
Multicentric Castleman's disease (MCD) is a rare polyclonal lymphoproliferative disorder that is typically accompanied by an overproduction of circulating cytokines (mainly interleukin-6). We here report the case of a 40-year-old HIV-negative woman with pulmonary manifestation of MCD. There is no standard treatment for MCD. In our patient, various treatment courses with immunomodulatory drugs were unsuccessful. Finally, treatment with the interleukin-6 receptor antibody tocilizumab has resulted in continual clinical improvement over the last 5 years.
Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Hiperplasia do Linfonodo Gigante/diagnóstico , Hiperplasia do Linfonodo Gigante/tratamento farmacológico , Tosse/diagnóstico , Tosse/tratamento farmacológico , Dispneia/diagnóstico , Dispneia/tratamento farmacológico , Adulto , Diagnóstico Diferencial , Feminino , Humanos , Resultado do TratamentoRESUMO
Our case illustrates the difficulties involved in diagnosing multicentric Castleman's disease (MCD) in a human immunodeficiency virus-infected man with febrile episodes and malaise. In the absence of well-established treatment protocols, we have chosen a new treatment algorithm with rituximab, etoposide, and valganciclovir, which led to the remission of clinical symptoms. Yet, we advocate focused exploration for MCD in immunosuppressed patients with unclear febrile episodes, as recent advances in treatment are promising.
Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Antivirais/uso terapêutico , Hiperplasia do Linfonodo Gigante/complicações , Infecções por HIV/complicações , Fatores Imunológicos/uso terapêutico , Convulsões Febris/etiologia , Algoritmos , Anticorpos Monoclonais Murinos/uso terapêutico , Hiperplasia do Linfonodo Gigante/tratamento farmacológico , Hiperplasia do Linfonodo Gigante/imunologia , Quimioterapia Combinada , Etoposídeo/uso terapêutico , Ganciclovir/análogos & derivados , Ganciclovir/uso terapêutico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Rituximab , Convulsões Febris/tratamento farmacológico , Convulsões Febris/imunologia , Resultado do Tratamento , ValganciclovirRESUMO
The role of cytology has so far been underrecognized in the diagnostic process of hematopathological questions. This article presents an algorithm which allows a stepwise work-up of cytology specimens obtained by minimally invasive ultrasound-guided fine needle aspiration in patients with unexplained lymph node swelling. Moreover, it is shown how the selective separation of cytology specimens allows the application of immunophenotypic analysis including flow cytometry and immunohistochemistry as well as molecular analyses, such as fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) strategies. With the integrative procedure presented, cytology offers an excellent cost-effective tool for the diagnostic approach of patients with suspected hematopathological malignancies allowing a high diagnostic accuracy, ideal for initial diagnosis or follow-up.
Assuntos
Técnicas Citológicas/métodos , Leucemia/patologia , Linfoma/patologia , Adulto , Idoso , Algoritmos , Biomarcadores Tumorais/genética , Biópsia por Agulha Fina/instrumentação , Biópsia por Agulha Fina/métodos , Southern Blotting/métodos , Técnicas Citológicas/instrumentação , Diagnóstico Diferencial , Desenho de Equipamento , Feminino , Citometria de Fluxo/instrumentação , Citometria de Fluxo/métodos , Humanos , Biópsia Guiada por Imagem/instrumentação , Biópsia Guiada por Imagem/métodos , Imuno-Histoquímica/instrumentação , Imuno-Histoquímica/métodos , Hibridização in Situ Fluorescente/instrumentação , Hibridização in Situ Fluorescente/métodos , Leucemia/genética , Metástase Linfática/patologia , Linfoma/genética , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase/métodos , Valor Preditivo dos Testes , Ultrassonografia de Intervenção/instrumentação , Ultrassonografia de Intervenção/métodosRESUMO
The rapid technological development in diagnostic pathology, especially of immunohistochemical and molecular techniques, also has a significant impact on diagnostic procedures for the evaluation of bone marrow trephine biopsies. The necessity for optimal morphology, combined with preservation of tissue antigens and nucleic acids on one hand and the wish for short turnaround times on the other hand require careful planning of the workflow for fixation, decalcification and embedding of trephines. Although any kind of bone marrow processing has its advantages and disadvantages, formalin fixation followed by EDTA decalcification can be considered a good compromise, which does not restrict the use of molecular techniques. Although the majority of molecular studies in haematological neoplasms are routinely performed on bone marrow aspirates or peripheral blood cells, there are certain indications, in which molecular studies such as clonality determination or detection of specific mutations need to be performed on the trephine biopsy. Especially, the determination of B- or T-cell clonality for the diagnosis of lymphoid malignancies requires stringent quality controls and knowledge of technical pitfalls. In this review, we discuss technical aspects of bone marrow biopsy processing and the application of diagnostic molecular techniques.
Assuntos
Biópsia por Agulha , Exame de Medula Óssea/métodos , Medula Óssea/patologia , Hibridização in Situ Fluorescente , Leucemia/genética , Leucemia/patologia , Linfoma/genética , Linfoma/patologia , Técnicas de Diagnóstico Molecular , Doenças Mieloproliferativas-Mielodisplásicas/genética , Doenças Mieloproliferativas-Mielodisplásicas/patologia , Biomarcadores Tumorais/genética , Aberrações Cromossômicas , Análise Mutacional de DNA , Marcadores Genéticos/genética , Imuno-Histoquímica/métodos , PrognósticoRESUMO
Cavitation bubbles collapsing and rebounding in a pressure gradient ∇p form a "microjet" enveloped by a "vapor jet." This Letter presents unprecedented observations of the vapor jets formed in a uniform gravity-induced ∇p, modulated aboard parabolic flights. The data uncover that the normalized jet volume is independent of the liquid density and viscosity and proportional to ζ ≡ |∇p|R(0)/Δp, where R(0) the maximal bubble radius and Δp is the driving pressure. A derivation inspired by "Kelvin-Blake" considerations confirms this law and reveals its negligible dependence of surface tension. We further conjecture that the jet only pierces the bubble boundary if ζ â³ 4 × 10(-4).
RESUMO
OBJECTIVE: Diagnosis of low grade non-Hodgkin B-cell lymphomas on cytological material may be problematic and in the past frequently required lymph node excision. We analysed our experience of the value of flow cytometry (FC) as an additional tool for the diagnosis of lymphoproliferative processes in the setting of a university cytology division with a busy fine needle cytology service. METHODS: Consecutive cytological specimens with FC over a period of 3 years were retrospectively analysed and correlated with histology and follow-up if available. FC was performed with the following antibodies: CD3, CD4, CD8, CD2, CD7, CD19, CD5, CD10, CD23, lambda and kappa chains. RESULTS: Of 299 probes (273 fine needle aspirations and 26 fluids from 285 patients), 179 cases (60%) were diagnosed as reactive, 91 cases (30%) as malignant or suspicious and 29 cases (10%) as inconclusive. The results of histological examination of the lymph nodes were available in 41 of 91 (45%) malignant or suspicious cases and in 13 of 179 (7%) reactive cytological diagnoses. Cytologically diagnosed malignancy was confirmed in all histologically examined cases. In 12 of 13 reactive cytological cases (92%), a benign process was diagnosed histologically. In 34 of 299 cases (11%) additional molecular investigations of B-cell clonality or specific translocations were performed. The lymphomas most frequently diagnosed were follicular lymphoma and lymphocytic lymphoma, followed by mantle cell and marginal zone lymphomas. Correlation with histology showed a sensitivity of 98% and a specificity of 100% for cytology in our series. CONCLUSIONS: FC is an important additional tool in the cytological diagnosis of lymphoproliferative disorders. The combined approach has a high diagnostic value that allows a reliable subclassification of low grade B-cell non-Hodgkin lymphomas.
Assuntos
Antígenos CD/análise , Citometria de Fluxo/métodos , Cadeias kappa de Imunoglobulina/análise , Linfoma não Hodgkin/química , Linfoma não Hodgkin/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biópsia por Agulha Fina/métodos , Criança , Feminino , Seguimentos , Humanos , Transtornos Linfoproliferativos/patologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Sensibilidade e EspecificidadeRESUMO
BACKGROUND: The diagnosis of a sinus fungus ball (SFB) is often not clear despite well-defined diagnostic criteria. OBJECTIVE: To study the radiological, intraoperative and histological diagnostic accuracy in comparison to results from mycological and histological analysis. METHODS: Systematic review of 724 files from patients treated for chronic rhinosinusitis from 1999 - 2006 at our institution. RESULTS: The sensitivity, specificity, positive and negative predictive value (PPV, NPV) of pre- operative CT imaging was 83%, 94%, 56% and 98% respectively, whereas, based on intra- operative findings, it was 98%, 93%, 57% and 100%. CONCLUSIONS: A high number of misdiagnoses was found possibly due to sampling error. A severe inflammatory reaction of the surrounding tissue was found more often in SFB than in controls in our study and this we suggest could be an additional sign for fungal infection. Fungal cultures did not contribute to a correct diagnosis.
Assuntos
Micoses/diagnóstico , Seios Paranasais/microbiologia , Rinite/microbiologia , Sinusite/microbiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Aspergillus fumigatus/isolamento & purificação , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Micoses/cirurgia , Seios Paranasais/diagnóstico por imagem , Seios Paranasais/cirurgia , Penicillium/isolamento & purificação , Radiografia , Estudos Retrospectivos , Rinite/diagnóstico por imagem , Rinite/cirurgia , Scedosporium/isolamento & purificação , Sensibilidade e Especificidade , Sinusite/diagnóstico por imagemRESUMO
Plasma cell myelomas (PMs) have a poor prognosis. Cancer-testis (CT) antigens are immunogenic proteins, representing potential targets for tumor vaccination strategies. The expression of the CT antigens GAGE, MAGE-A4, MAGE-C1/CT-7, and NY-ESO-1 was investigated on paraffin-embedded bone marrow biopsies from 219 PM and 8 monoclonal gammopathy of undetermined significance (MGUS) patients. The frequency and prognostic impact of these CT antigens were compared with known morphological prognostic markers (i.e. Mib1 labeling index) and the presence of the translocations t(4;14)(p16.3; q32) and t(11;14)(q13;q32). We show that MAGE-C1/CT-7 is the most prevalent CT antigen, expressed in 57% of PMs in a high percentage of tumor cells. While MAGE-C1/CT-7 was absent in non-malignant plasma cells, plasma cells of patients with MGUS did express MAGE-C1/CT-7, but no other CT antigens. MAGE-C1/CT-7 was more frequently expressed in PMs with an elevated proliferation rate (Mib1 >10%) compared to PMs with a low proliferation rate (Mib1 Assuntos
Antígenos de Neoplasias/análise
, Mieloma Múltiplo/diagnóstico
, Mieloma Múltiplo/mortalidade
, Proteínas de Neoplasias/análise
, Adulto
, Idoso
, Feminino
, Humanos
, Masculino
, Pessoa de Meia-Idade
, Mieloma Múltiplo/patologia
, Prognóstico
, Análise de Sobrevida
RESUMO
AIMS: Accurate classification of haematological malignancies is a prerequisite for their correct diagnosis, prognosis and therapy. Clear classification of lymphomas is often hindered by the limited number of available cell surface protein markers that are suitable for immunophenotyping. A systematic and quantitative analysis of cell surface proteins is thus required to identify new protein markers on lymphoma subtypes in an unbiased and discovery-driven approach. METHODS: Nine Hodgkin and non-Hodgkin B cell lines of diffuse large cell type and mediastinal type were investigated by cell surface capture (CSC) technology, a mass spectrometry-based method to identify cell surface glycoproteins. Selected proteins are verified by antibody-based methods, including flow cytometry and immunohistochemistry on cell line arrays. RESULTS: A total of 747 predicted transmembrane proteins were identified from all cell lines, including 142 CD (cluster of differentiation) annotated proteins. A group of differentially expressed cell surface glycoproteins between Hodgkin and non-Hodgkin B cell lines was revealed via quantitative CSC technology. In addition to classical and expected CD molecules such as CD20 and CD30, less frequently expressed molecules such as CD2 on Hodgkin lymphoma (HL) cell lines were identified by CSC and verified by immunohistochemistry in cell lines and primary lymphoma tissue. A panel of CSC-identified differentiation glycoprotein candidates is currently under investigation on tissue microarrays (TMAs) from patient samples.
Assuntos
Doença de Hodgkin/classificação , Doença de Hodgkin/diagnóstico , Imunofenotipagem/métodos , Linfoma de Células B/classificação , Linfoma de Células B/diagnóstico , Linfoma Difuso de Grandes Células B/classificação , Linfoma Difuso de Grandes Células B/diagnóstico , Neoplasias do Mediastino/classificação , Neoplasias do Mediastino/diagnóstico , Proteínas de Membrana/análise , Linhagem Celular Tumoral , Humanos , Espectrometria de Massas , Glicoproteínas de Membrana/análise , Valor Preditivo dos TestesRESUMO
Clonally related composite lymphomas of Hodgkin's lymphoma (HL) and Non-Hodgkin's lymphoma (NHL) represent models to study the multistep transformation process in tumorigenesis and the development of two distinct tumors from a shared precursor. We analyzed six such lymphomas for transforming events. The HLs were combined in two cases with follicular lymphoma (FL), and in one case each with B-cell chronic lymphocytic leukemia, splenic marginal zone lymphoma, mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). In the HL/FL and HL/MCL combinations, BCL2/IGH and CCND1/IGH translocations, respectively, were detected in both the HL and NHL. No mutations were found in the tumor suppressor genes FAS, NFKBIA and ATM. The HL/DLBCL case harbored clonal replacement mutations of the TP53 gene on both alleles exclusively in the DLBCL. In conclusion, we present the first examples of molecularly verified IgH-associated translocations in HL, which also show that BCL2/IGH or CCND1/IGH translocations can represent early steps in the pathogenesis of composite HL/FL or HL/MCL. The restriction of the TP53 mutations to the DLBCL in the HL/DLBCL case exemplifies a late transforming event that presumably happened in the germinal center and affected the fate of a common lymphoma precursor cell towards development of a DLBCL.
Assuntos
Transformação Celular Neoplásica/genética , Genes Supressores de Tumor , Cadeias Pesadas de Imunoglobulinas/genética , Linfoma/patologia , Mutação , Translocação Genética , Transformação Celular Neoplásica/patologia , Células Clonais , Ciclina D1/genética , Genes bcl-2 , Doença de Hodgkin/patologia , Humanos , Linfoma/etiologia , Linfoma/genética , Linfoma não Hodgkin/patologia , Proteína Supressora de Tumor p53/genéticaRESUMO
Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival.
Assuntos
Ciclo-Oxigenase 2/metabolismo , Mieloma Múltiplo/enzimologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Progressão da Doença , Feminino , Humanos , Imuno-Histoquímica/métodos , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/metabolismo , Mieloma Múltiplo/patologia , Modelos de Riscos Proporcionais , Análise de SobrevidaRESUMO
According to the current WHO classification of haematopoietic and lymphoid tissue, recurrent genetic aberrations constitute diagnostic markers for the histomorphological diagnosis of malignancies in these tissues. In lymphoma, translocations represent such genetic aberrations. Apart from their diagnostic impact, there is increasing evidence for their prognostic and predictive value. Despite the numerous translocations known in Non-Hodgkin's lymphoma (NHL), few are applied in routine diagnostics on a regular basis. To date, translocations have gained particular significance in B-cell NHLs, in contrast to T-cell NHLs where few are characterised. Refined tissue processing facilitates determination of translocations not only in fresh tissue, but increasingly also informalin fixed, paraffin embedded, and even decalcified biopsies. Hybridisation procedures (Southern blotting, FISH) and gene amplification methods (PCR, RT-PCR) are the primary molecular techniques employed to identify translocations. The article deals with the advantages and disadvantages of the currently used molecular techniques for the investigation of translocations in routine hematopathology diagnostics.
Assuntos
Linfoma não Hodgkin/genética , Translocação Genética , Apoptose , Biópsia , Southern Blotting , Citogenética , Diagnóstico Diferencial , Humanos , Hibridização in Situ Fluorescente , Linfoma de Células B/diagnóstico , Linfoma de Células B/genética , Linfoma de Células B/patologia , Linfoma não Hodgkin/diagnóstico , Linfoma não Hodgkin/patologia , Linfoma de Células T/diagnóstico , Linfoma de Células T/genética , Linfoma de Células T/patologia , Técnicas de Diagnóstico Molecular , Inclusão em Parafina , Reação em Cadeia da Polimerase , Valor Preditivo dos Testes , Prognóstico , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Organização Mundial da SaúdeRESUMO
Chronic B-cell lymphocytic leukaemia (CLL) and low-grade B-cell Non Hodgkin's lymphomas (Lg-NHL) are characterized by slow accumulation of neoplastic cells arrested in the G0/G1 phase of the cell cycle. In contrast, proliferation rates are high in aggressive B-cell lymphomas (Hg-NHL). Divergent expression of cyclin-dependent kinase inhibitors (CKI) in the cell cycle may contribute to these differences. We analysed CLL as well as low and high grade B-cell NHL for expression of G1-specific and universal CKI by competitive RT-PCR and immunostaining. p16(INK4A) expression was low in all types of neoplasms. Highest p14(ARF) /p16 beta expression levels were found in normal lymphocytes. Expression of this CKI was significantly lower in CLL, but still higher in CLL than in the lymphomas (median 27 vs. 3 mRNA transcripts x 10(3), p = 0.0001). p14(ARF) /p16 beta immunostaining correlated with mRNA expression. Highest p21 mRNA levels were found in CLL, but three of four CLL with abundant p21 mRNA production were negative on immunostaining. High grade lymphomas showed markedly decreased p21 expression (3.9 in Hg-NHL vs. 12 in Lg-NHL and 29 in CLL; values expressed as mRNA transcripts x 10(3), p < 0.009). mRNA and protein expression of p27 was considerably higher in CLL than in the lymphomas. Differential CKI expression in various B-cell neoplasias may provide important biological markers, if not the molecular underpinning of their different cell cycle kinetics. Targeted interference with such genes governing cell cycle control in lymphoid neoplasia may pave the way towards new treatment strategies.
Assuntos
Proteínas de Ciclo Celular/biossíntese , Inibidor p16 de Quinase Dependente de Ciclina/biossíntese , Regulação Neoplásica da Expressão Gênica , Genes p16 , Leucemia Linfocítica Crônica de Células B/genética , Linfoma não Hodgkin/genética , Proteínas de Neoplasias/biossíntese , Proteína Supressora de Tumor p14ARF/biossíntese , Proteínas Supressoras de Tumor/biossíntese , Adulto , Idoso , Idoso de 80 Anos ou mais , Proteínas de Ciclo Celular/genética , Divisão Celular , Inibidor de Quinase Dependente de Ciclina p15 , Inibidor p16 de Quinase Dependente de Ciclina/genética , Inibidor de Quinase Dependente de Ciclina p21 , Inibidor de Quinase Dependente de Ciclina p27 , Ciclinas/biossíntese , Ciclinas/genética , Feminino , Regulação Leucêmica da Expressão Gênica , Humanos , Leucemia Linfocítica Crônica de Células B/metabolismo , Linfoma não Hodgkin/metabolismo , Masculino , Pessoa de Meia-Idade , RNA Mensageiro/biossíntese , RNA Neoplásico/biossíntese , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Proteínas Supressoras de Tumor/genéticaRESUMO
Recent studies have shown marked geographic variation associated with Epstein-Barr virus (EBV) in pediatric Burkitt's lymphomas and Hodgkin's disease. In the present study we investigated 30 cases of pediatric extranodal high grade non-Hodgkin's lymphomas (NHL) from Turkey with an abdominal localisation. To classify them histologically and to determine the role of EBV in these lymphomas, immunohistochemistry (IHC), in situ hybridisation (ISH) and polymerase chain reaction (PCR) were used. Our series contained two histologic types: the Burkitt's or Burkitt's-like lymphomas (BL/BLL) and high grade NHL. They all were of the B cell type. The immunoglobulin heavy chain gene rearrangement revealed monoclonality in 87% of the BL/BLL cases, in contrast to the NHL cases, showing monoclonality in only 43% of the cases. EBV was found in tumor cells in a high frequency, independent of the histological subtype. EBV strains A and B were detected in 9 cases, with a preponderance of the B subtype (4/9 BL/BLL; 4/9 NHL). Our data suggest that high grade NHLs with abdominal localisation of Turkish children show the pattern of immunodeficient lymphomas to some extent.
Assuntos
Neoplasias Abdominais/virologia , Infecções por Vírus Epstein-Barr/diagnóstico , Linfoma não Hodgkin/virologia , Neoplasias Abdominais/patologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Linfoma não Hodgkin/patologia , Masculino , TurquiaRESUMO
Spherically collapsing cavitation bubbles produce a shock wave followed by a rebound bubble. Here we present a systematic investigation of the energy partition between the rebound and the shock. Highly spherical cavitation bubbles are produced in microgravity, which suppresses the buoyant pressure gradient that otherwise deteriorates the sphericity of the bubbles. We measure the radius of the rebound bubble and estimate the shock energy as a function of the initial bubble radius (2-5.6mm) and the liquid pressure (10-80kPa). Those measurements uncover a systematic pressure dependence of the energy partition between rebound and shock. We demonstrate that these observations agree with a physical model relying on a first-order approximation of the liquid compressibility and an adiabatic treatment of the noncondensable gas inside the bubble. Using this model we find that the energy partition between rebound and shock is dictated by a single nondimensional parameter ξ=Δpγ6/[p(g0)1/γ(ρc2)1-1/γ], where Δp=p∞ - pv is the driving pressure, p∞ is the static pressure in the liquid, pv is the vapor pressure, pg0 is the pressure of the noncondensable gas at the maximal bubble radius, γ is the adiabatic index of the noncondensable gas, ρ is the liquid density, and c is the speed of sound in the liquid.
RESUMO
Toll-like receptor 9 (TLR9) triggering is a promising novel strategy to combat cancer as it induces innate and adaptive immunity responses. B-cell lymphoma is unique in this context as tumor cells express TLR9 and may harbor latent Epstein-Barr virus (EBV), a gamma-herpesvirus with remarkable oncogenic potential when latent. Latent EBV may be promoted by TLR9 triggering via suppression of lytic EBV. Here, we elaborated an initial assessment of the impact of TLR9 triggering on EBV-positive and EBV-negative B-cell lymphoma using Burkitt's lymphoma (BL) cell lines as an in vitro model. We show that, independent of the presence of EBV, the TLR9 ligand oligodeoxynucleotide (ODN) CpG-2006 may or may not induce caspase-dependent cell death in BL cells. Moreover, ODN CpG-2006-induced cell death responses of BL cells were associated with TLR9 single-nucleotide polymorphisms (SNPs) rs5743836 or rs352140, which we detected in primary BL tumors and in peripheral blood from healthy individuals at similar frequencies. Thus, our findings suggest that the effect of TLR9 agonists on BL cells should be tested in vitro before installment of therapy and TLR9 SNPs in BL patients should be determined as potential biological markers for the therapeutic response to treatment targeting innate immunity.